MYNZ – mainz biomed n.v. - ordinary shares (US:NASDAQ)

News

Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test
Mainz Biomed Announces Closing of $8.0 Million Follow-On Offering
Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq Rules
Mainz Biomed Announces Stock Split
Mainz Biomed (NASDAQ: MYNZ) was downgraded by analysts at HC Wainwright from a "buy" rating to a "neutral" rating.
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com